IBT.B Statistics

Total Valuation

Infant Bacterial Therapeutics AB has a market cap or net worth of SEK 1.35 billion. The enterprise value is 1.07 billion.

Market Cap	1.35B
Enterprise Value	1.07B

Important Dates

The next estimated earnings date is Thursday, November 14, 2024.

Earnings Date	Nov 14, 2024
Ex-Dividend Date	n/a

Share Statistics

Infant Bacterial Therapeutics AB has 13.47 million shares outstanding. The number of shares has increased by 0.03% in one year.

Shares Outstanding	13.47M
Shares Change (YoY)	+0.03%
Shares Change (QoQ)	+0.88%
Owned by Insiders (%)	3.82%
Owned by Institutions (%)	63.00%
Float	11.78M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	19,550.34
PB Ratio	5.69
P/FCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-7.55
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.80

Current Ratio	4.80
Quick Ratio	4.61
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -54.97% and return on invested capital (ROIC) is -37.06%.

Return on Equity (ROE)	-54.97%
Return on Assets (ROA)	-31.25%
Return on Capital (ROIC)	-37.06%
Revenue Per Employee	8,625
Profits Per Employee	-17.78M
Employee Count	8
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +20.19% in the last 52 weeks. The beta is 1.13, so Infant Bacterial Therapeutics AB's price volatility has been higher than the market average.

Beta (5Y)	1.13
52-Week Price Change	+20.19%
50-Day Moving Average	103.30
200-Day Moving Average	94.32
Relative Strength Index (RSI)	42.91
Average Volume (20 Days)	19,598

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Infant Bacterial Therapeutics AB had revenue of SEK 69,000 and -142.27 million in losses. Loss per share was -10.55.

Revenue	69,000
Gross Profit	69,000
Operating Income	-153.45M
Pretax Income	-142.27M
Net Income	-142.27M
EBITDA	n/a
EBIT	-153.45M
Loss Per Share	-10.55

Balance Sheet

Cash & Cash Equivalents	272.51M
Total Debt	n/a
Net Cash	272.51M
Net Cash Per Share	20.23
Equity (Book Value)	236.68M
Book Value Per Share	17.57
Working Capital	227.31M

Cash Flow

Operating Cash Flow	-120.80M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	100.00%
Operating Margin	-222,385.51%
Pretax Margin	-206,186.96%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Infant Bacterial Therapeutics AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.03%
Shareholder Yield	-0.03%
Earnings Yield	-10.55%
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a